{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-099824","form_type":"8-K","ticker":"ELV","cik":"0001156039","company_name":"Elevance Health, Inc.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.469363+00:00","generated_at":"2026-06-03T18:09:21.756857+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Elevance Health Q1 diluted EPS $9.59 (+15.5%); raises FY2024 adj. EPS guidance to >$37.20","bullets":["Q1 operating revenue $42.3B (+0.9% YoY); diluted EPS $9.59 (+15.5%); adjusted diluted EPS $10.64 (+12.5%).","Benefit expense ratio 85.6%, improving 20 bps; operating margin 7.1% vs 6.8% YoY.","Medical membership 46.2M, down 1.9M YoY due to Medicaid attrition, partially offset by commercial growth.","Carelon revenue $12.1B (+5%); operating gain $0.8B (+10%).","FY2024 guidance raised: diluted EPS >$34.05, adjusted >$37.20; strategic partnership with CD&R for primary care."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-099824","json":"https://secwatch.observer/filing/0001193125-24-099824.json","markdown":"https://secwatch.observer/filing/0001193125-24-099824.md","text":"https://secwatch.observer/filing/0001193125-24-099824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524099824/0001193125-24-099824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524099824/d813732d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T18:09:21.756857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"270c30fd0365b907056a09d873d4317074bbb7bf","claim":"Elevance Health, Inc. reported the quarter ended March 31, 2024 results: revenue $42.3 billion, EPS $9.59. Guidance raised.","evidence_excerpt":"language in such filings. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 EARNINGS RELEASE ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS • 1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 • 1Q 2024 diluted EPS 1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS 2 of $10.64, up 12.5% • FY 2024 diluted EPS and adjusted diluted EPS","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1156039/000119312524099824/0001193125-24-099824-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$42.3 billion"},{"label":"EPS","value":"$9.59"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}